<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179890</url>
  </required_header>
  <id_info>
    <org_study_id>1200-0316</org_study_id>
    <nct_id>NCT04179890</nct_id>
  </id_info>
  <brief_title>The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib</brief_title>
  <acronym>UpSwinG</acronym>
  <official_title>UpSwinG: Real World Study on TKI Activity in Uncommon Mutations and Sequencing Giotrif®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, multi-country, multi-centre cohort study based on existing data from&#xD;
      medical records (paper or electronic) or electronic health records of patients with advanced&#xD;
      NSCLC harbouring EGFR mutations and treated with an EGFR-TKI&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Actual">July 22, 2021</completion_date>
  <primary_completion_date type="Actual">July 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time on treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>assessed as the time from start of EGFR-TKI treatment until the end of treatment or death date by any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall response</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on treatment until failure of second-line (TTF2)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>uncommon mutation cohort only</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Non-squamous, Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Uncommon mutation cohort</arm_group_label>
    <description>Patients with non-small-cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequencing cohort</arm_group_label>
    <description>Patients with non-small-cell lung cancer (NSCLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidermal Growth Factor Tyrosine Kinase Inhibitor</intervention_name>
    <description>Up to 30 months</description>
    <arm_group_label>Uncommon mutation cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Up to 30 months</description>
    <arm_group_label>Sequencing cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor&#xD;
        (EGFRTKI) naïve advanced EGFR mutated non-small cell lung cancer (NSCLC),&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients&#xD;
&#xD;
          2. Diagnosed with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFRTKI)&#xD;
             naïve advanced EGFR mutated non-small cell lung cancer (NSCLC),&#xD;
&#xD;
          3. treated for Epidermal Growth Factor Receptor (EGFR) mutated NSCLC within regular&#xD;
             clinical practice.&#xD;
&#xD;
          4. Informed and privacy consent signature must be obtained depending on local&#xD;
             regulations.&#xD;
&#xD;
             More specific inclusion criteria for each cohort are the following:&#xD;
&#xD;
             Uncommon mutation cohort:&#xD;
&#xD;
          5. Patients harbouring uncommon or compound EGFR mutations&#xD;
&#xD;
          6. Patients who started with either afatinib (Gi(l)otrif®), gefitinib (Iressa), erlotinib&#xD;
             (Tarceva), or osimertinib (Tagrisso) in the first- or second-line setting within&#xD;
             regular clinical practice&#xD;
&#xD;
          7. Patients must have started EGFR-TKI treatment at least 12 months prior to data entry.&#xD;
&#xD;
        Sequencing cohort:&#xD;
&#xD;
        5. Patients with common EGFR mutations (Del19, L858R) 6. Patients were treated with&#xD;
        afatinib (Gi(l)otrif®) in the first-line setting and for acquired T790M mutation with&#xD;
        osimertinib in the second line; 7. Patients must have started osimertinib treatment at&#xD;
        least 10 months prior to data entry.&#xD;
&#xD;
        Patients treated with osimertinib within an early access program/ compassionate use program&#xD;
        (EAP/CUP) are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients treated for EGFR mutated NSCLC within a clinical trial or participated in&#xD;
             GioTag study.&#xD;
&#xD;
          2. Patients with active brain metastases at start of EGFR-TKI therapy (independent of&#xD;
             treatment line)&#xD;
&#xD;
          3. For uncommon mutation cohort: Patients treated with osimertinib with no further&#xD;
             uncommon mutation than acquired T790M Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

